
AstraZeneca to Establish Global Drug Research Center in Beijing
Britain’s AstraZeneca wants to invest $2.5 billion in Beijing, China to establish its sixth global strategic R&D center.
Britain’s AstraZeneca wants to invest $2.5 billion in Beijing, China to establish its sixth global strategic R&D center.
To support the move to a larger office facility in the Greater Toronto Area, Ontario, AstraZeneca plans to invest $570 million in Canada, creating more than 700 jobs.
Avantor has opened its latest Innovation Center in Bridgewater, New Jersey, US, “to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows.” The new center is now part of the company’s network of 13 global research and innovation centers.
Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.
Manual experiment monitoring and data capture is still the status quo in most biotech and pharma labs, compromising efficiency and project timescales. But there is a better way.
The Spanish computational chemistry start-up Nextmol (Bytelab Solutions), a spin-off from the Barcelona Supercomputing Centre, offers a software-as-a-service (SaaS) platform that accelerates research and innovation in sustainable specialty chemicals through “in silico” experiments using molecular modeling and artificial intelligence (AI).
UK’s Elementis, a global specialty chemicals company, will be opening a new unit in Portugal, featuring a center of excellence and R&D laboratory. The new unit, which will be headquartered in Porto and is scheduled to open in the first half of 2024, will support the company’s business segments Personal Care and Performance Specialties and also reinforce the current R&D capacity of the Elementis' laboratories in Asia and the Americas.
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a major revision of pharmaceutical regulations as proposed by the European Commission in April this year could shrink Europe's share of global research and development by a third to 21% by 2040, resulting in a loss of investment of €2 billion ($2.15 billion) a year.
DMC Biotechnologies announced a new 880 square meter (9,500 square foot) metabolic engineering and fermentation facility in North Carolina, to support a team of scientists advancing DMC products and active collaborations.
With the inauguration of a new research building in the Shanghai Technology Park, Solvay has completed the expansion of its China Research & Innovation Center (R&I). The company said that it has invested more than 4 billion RMB (approximately €500 million) in its Chinese R&I hub since 2005.